Genenta Science (NASDAQ:GNTA) (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.
Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter. Temferon is currently being evaluated in Phase I/II clinical trials for recurrent high-grade glioma and ovarian carcinoma. Early clinical data have demonstrated a favorable safety profile and promising signs of biological activity, supporting the company’s approach to create a durable anticancer effect while limiting systemic toxicity.
Headquartered in Milan, Italy, with a research and development presence in the United States, Genenta Science collaborates with academic institutions and cancer centers across Europe and North America to advance its clinical programs. The company benefits from strategic partnerships that provide access to leading oncology experts, manufacturing capabilities, and patient networks, positioning it to accelerate enrollment in multi-center trials and to expand its pipeline.
Founded in 2016 as a spin-off from leading academic research institutes, Genenta Science is led by a management team with extensive experience in gene therapy, hematology, and oncology drug development. The company has attracted funding from both private investors and non-dilutive sources to support its growth, with the goal of bringing novel HSC-based immunotherapies to patients with hard-to-treat solid tumors.
